Rituximab monotherapy for patients with recurrent primary cns lymphoma

Neurology

Volumn 76, Issue 10, 2011, Pages 929-930

  Batchelor, T T ^a,e   Grossman, S A ^b   Mikkelsen, T ^c   Ye, X ^b   Desideri, S ^b   Lesser, G J ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d WAKE FOREST BAPTIST HEALTH   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; LYMPHOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; LYMPHOMA; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; ODDS RATIO; PILOT PROJECTS;

EID: 79952908275     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31820f2d94     Document Type: Article

References (6)

1. Shah G, Yahalom J, Correa D, et al. Combined immuno-chemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007;25:4730-4735. (Pubitemid 350086474)
2. Enting R, Demopoulos A, DeAngelis L, Abrey L. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004;63:901-903. (Pubitemid 39297656)
3. Rubenstein JL, Rosenberg J, Damon L. High-dose metho-trexate plus rituximab (Anti-CD20) monoclonal antibody in the treatment of primary CNS lymphoma. Society for Neuro-Oncology fourth annual meeting, Scottsdale, AZ, November 17-21, 1999. Abstract.
4. 123-labeled rituximab. Eur J Haematol 2005;74:348-352. (Pubitemid 40461156)
5. Maza S, Kiewe P, Munz DL, et al. First report on a prospective trial with yttrium-90-labeled ibritumomab tiux-etan (Zevalin) in primary CNS lymphoma. Neurooncol 2009;11:423-429.
6. Macdonald DR, Cascino TL, Schold SC, Cairncross J. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280. (Pubitemid 20195640)